Pharma BD Deal Intelligence

Merck & Co. Inc. / Eisai Co., Ltd.

2017 · Co-Development · $5.8B · Complete

Merck and Eisai entered a global strategic oncology collaboration to co-develop and co-commercialize lenvatinib (LENVIMA) as monotherapy and in combination with KEYTRUDA (pembrolizumab). Eisai received $300M upfront, up to $650M in option exercise rights through 2020, $450M in R&D reimbursement, plus up to $385M in clinical/regulatory milestones and up to $3.97B in sales-based milestones (~$5.76B aggregate). Eisai books global sales; gross profits split 50/50.

Key facts

• Announced Mar 07, 2017
• Closed Mar 07, 2017
• Deal value $5.8B
• Deal type Co-Development
• Therapeutic area Renal cell carcinoma, hepatocellular carcinoma, endometrial cancer (in combination with KEYTRUDA)
• Indications Renal cell carcinoma, hepatocellular carcinoma, endometrial cancer (in combination with KEYTRUDA)
• Key assets LENVIMA (lenvatinib mesylate)
• Mechanism Multi-receptor tyrosine kinase inhibitor (VEGFR1-3, FGFR1-4, RET, KIT, PDGFR-alpha)

← Browse all deals  ·  How we score deals